UNSPSC 51342706: Interferon alfa-2b

This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43K1W2T1M6, also known as human leucocyte clone pm21 protein moiety reduced. European Medicines Agency schedules Interferon alfa-2a in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12521MIG. As of Q4 2014, INTERFERON ALFA-2B remains the US FDA Preferred Term for this commodity. SMILES: NONE.

UNSPSC 51342706 Interferon alfa-2b, a Commodity code, does not match the work actually being solicited under recent state and local opportunities. The source shows no active or awarded state and local contracts for interferon alfa-2b. The most-recent-state-local-contract-opportunities block instead documents a completed pharmaceutical warehouse award by the Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (unrelated antibiotics), and a Seminole County, Florida procurement for naloxone and drug deactivation systems. Neither opportunity involves interferon alfa-2b.

The code shows little relevant recent activity. Interferon alfa-2b is a specialized antiviral pharmaceutical with a narrow therapeutic market; state and local health departments and purchasing cooperatives buy it through existing piggyback contracts, group purchasing organization frameworks like MMCAP, and standing warehouse agreements rather than through open competitive solicitations. No open RFP, RFQ, IFB, or ITB for interferon alfa-2b is present in the recent-opportunities block. This code should be approached with caution — opportunities are likely to appear through cooperative purchasing vehicles or as line items embedded within broader pharmaceutical framework agreements rather than as standalone competitive solicitations.